2019.Aug.03
IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, submission to FDA
Date of occurrence of the event: Aug 03, 2019 Company name: OBI Pharma Inc. Relationship to the Company (please enter “head office” or “subsidiaries”): Head Office Reciprocal shareholding ratios: Not applicable Cause of occurrence: Head office filed IND Phase I/II Human Clinical Trial Application of Globo-H Antibody-Drug Conjugate, OBI-999, to FDA Countermeasures: None Any other […]
This article is password protected.
To view the content, please enter your password in the field below